Sign in
Back
Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
Journal article   Peer reviewed

Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.

Tracy B. Bramlette, David H. Lawson, Carl V. Washington, Emir Veledar, Barry R. Johns, Stacey F. Brisman, Liana Abramova and Suephy C. Chen
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], Vol.33(1), pp.11-16
2007
DOI: https://doi.org/10.1111/j.1524-4725.2007.33001.x

Abstract

BACKGROUNDPatients with thick (Breslow >4 mm) primary melanoma and/or regional nodal metastasis have a high risk of tumor recurrence. High-dose adjuvant interferon (IFN) alfa-2b offers ≤10% improvement in relapse-free survival and overall survival with significant toxicity.OBJECTIVEThe objective was
url
https://lens.org/028-399-307-038-497View
url
https://www.ncbi.nlm.nih.gov/pubmed/17214673View
url
https://europepmc.org/article/MED/17214673View
url
https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1524-4725.2007.33001.xView

Metrics

1 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.158 Dermatology - General
1.158.201 Melanoma
Web Of Science research areas
Dermatology
Surgery
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details